--- title: "Weekly Recap | 10X Genomics -13.38%, consensus target above spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/302175877.md" description: "10X Genomics fell 13.38% to close at $69.86 this week, against a 1.95% drop in the S&P 500, leaving the stock about 11.43 percentage points behind the benchmark. The week had a distinctly defensive feel. Monday opened at $79.18 and touched a weekly high of $80.472 before the sell-off took hold; Tuesday and Wednesday kept price between $71 and $74, and Friday slid to a weekly low of $67.52 before settling at $69.86." datetime: "2026-10-17T08:19:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302175877.md) - [en](https://longbridge.com/en/news/302175877.md) - [zh-HK](https://longbridge.com/zh-HK/news/302175877.md) generator: "portal-rs" --- # Weekly Recap | 10X Genomics -13.38%, consensus target above spot ## The Week 10X Genomics fell 13.38% to close at $69.86 this week, against a 1.95% drop in the S&P 500, leaving the stock about 11.43 percentage points behind the benchmark. The week had a distinctly defensive feel. Monday opened at $79.18 and touched a weekly high of $80.472 before the sell-off took hold; Tuesday and Wednesday kept price between $71 and $74, and Friday slid to a weekly low of $67.52 before settling at $69.86. ## Key Events The most direct company news was the announcement that 10X Genomics will report third-quarter results on 5 November 2026. Separately, some analysts adjusted their views during the week: one 12-month price target was raised to $74.13, though at the time that still implied roughly 8% downside, highlighting the gap between current valuation and growth expectations. On Thursday, the stock was down 4.34% in pre-market trading and appeared on several active pre-market lists. Reports of Cathie Wood cutting about $11 million in genetic testing exposure added to the cautious mood. ## Analyst Ratings 19 brokers cover 10X Genomics: 12 rate it hold, 6 rate it buy, and 1 rates it an overweight stance. The consensus recommendation is buy, with a consensus target of $77, about 10.22% above the $69.86 spot price. Individual targets range from $50 to $110, a wide spread that reflects divergent views. Within the life sciences tools and services industry, the stock ranks ninth out of 54 names. ## The Week Ahead US housing and crude inventory data from 19 to 21 October could influence risk appetite for growth names. The larger catalyst is the third-quarter earnings release on 5 November after market close, where the market expects EPS of -$0.2585 and revenue of $148 million. That print will test whether the recent pullback has brought expectations back in line with fundamentals. ## In Short The week’s decline came while the consensus target still sat above spot and the stock’s industry rating rank remained in the top half, but the $50 to $110 target range shows how divided the Street remains on growth. The latest session’s flows also pointed to small and medium orders on the buy side and large orders on the sell side, in line with the down move. The key now is whether the 5 November earnings can confirm third-quarter growth and steer the debate away from macro-driven selling. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TXG.US](https://longbridge.com/en/quote/TXG.US.md) ## Related News & Research - [10x Genomics (NASDAQ:TXG) Given Equal Weight Rating at Stephens](https://longbridge.com/en/news/302916255.md) - [10x Genomics (TXG) Expands Fred Hutch Cancer Work, Is The Valuation Case Still Convincing?](https://longbridge.com/en/news/302193585.md) - [J.P. Morgan Reaffirms Their Hold Rating on 10x Genomics (TXG)](https://longbridge.com/en/news/302183593.md) - [Throwback to Nebius stock losing a third after Meta's AI cloud move](https://longbridge.com/en/news/302964390.md) - [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**